Search
Selected Filters
Displaying 1–10 of 17 news results
-
The Foundation Makes an Impact on Retinal Research
Foundation NewsThe Foundation Fighting Blindness’ long-term impact on moving the inherited retinal disease field forward towards treatments and cures.
-
Foundation Summit Highlights Robust Growth in Commercial Development for Retinal Disease Therapies
Foundation NewsThe Foundation’s Investing in Cures Summit (ICS), held on April 2, 2022, in Half Moon Bay, California, convened 175 researchers, industry executives, and constituents to present and discuss the expanding and accelerating commercial development of emerging therapies for retinal degenerative diseases.
-
Statement from Ben Yerxa, PhD, about Paralympian Becca Meyers
Foundation NewsThe Foundation believes that all people with disabilities should receive the accommodations necessary for their inclusion in all facets of society, especially when an individual may be unfamiliar with the area.
-
Foundation and Vision Partners Seek Biomedical Research Support from Congress during COVID-19 Crisis
Foundation NewsDelays in Research Impacting Therapy Development
-
Foundation News
The Foundation Fighting Blindness is closely monitoring the COVID-19 situation and its impact on the IRD community.
-
7th Annual Retinal Cell and Gene Therapy Innovation Summit
Foundation NewsPlease note that the seventh annual Retinal Cell and Gene Therapy Innovation Summit previously scheduled for Friday, May 1st, 2020 in Baltimore, Maryland has been cancelled.
-
VISIONS 2020 Conference registration now open
Foundation NewsThe Foundation Fighting Blindness VISIONS 2020 conference will be held on June 18-20th at the Hyatt Regency Minneapolis.
-
Foundation Fighting Blindness Investing Nearly $6.5 Million in New Grants
Foundation NewsThe newly funded research efforts include several therapies that have strong potential to treat a wide range of inherited retinal diseases.
-
Tackling the Next Gene Therapy Challenge: Autosomal Dominant Diseases
Foundation NewsA discussion of strategies concerning the development of autosomal dominant disease therapies at the Translational Research Acceleration Program (TRAP) in November 2013.
